Tariff Restructuring of the Global Generic Drug Industry: Economic博弈, Reshoring Dilemmas, and Global Trade Realignment in India’s $30 Billion Pharmaceutical Sector under U.S. Tiered Tariffs of up to 200%

Chapter III: Dual Dilemmas Facing Indian Pharmaceutical Companies — Unabsorbable Tariff Costs and Systemic Economic Barriers to Production Relocation to the U.S. 3.1 Under a Thin-Margin Business Model, There Is No Room to Absorb High Tariffs The perfectly competitive nature of the generic drug market deprives companies of pricing autonomy—this is the core economic pain point preventing Indian pharmaceutical firms from bearing 100%–200% tariffs. Dr. Reddy’s Laboratories CEO Erez Israeli explicitly stated in a CNBC interview: producing low-margin generics domestically in the U.S. is economically unviable; high tariffs cannot reduce raw material costs nor be offset through internal cost-cutting. First, raw material costs are highly inflexible. India imports 80% of its critical active pharmaceutical ingredients (APIs); APIs account for over 60% of generic drug production costs. The global API market is likewise highly concentrated, leaving little room for substantial price reductions. Even if Indian firms cut management, labor, and energy expenses, such optimizations would yield less than 5% of total cost savings—utterly insufficient against tariff hikes doubling or tripling production costs. Second, the U.S. procurement system imposes extreme price pressure and prohibits arbitrary price increases. U.S. pharmacies and health insurance groups lock in generic drug purchase prices via annual tenders, with contract durations of one to three years; mid-contract price hikes result directly in loss of large-volume orders. Given the high degree of product homogeneity among generics, any price increase by Indian manufacturers would prompt swift market capture by European, Canadian, and Israeli generic producers—leaving Indian firms trapped between losing orders if they raise prices and operating at a loss if they do not. Third, small- and medium-sized enterprises (SMEs) possess weak financial reserves and extremely poor risk resilience. While leading Indian pharma firms have the capital capacity for overseas M&A and cross-border factory construction, thousands of SME exporters operate with limited asset bases and cash flows sufficient only for day-to-day operations—lacking the tens or hundreds of millions of dollars required for U.S. plant establishment. Once tariffs take effect as scheduled, SMEs will exit the U.S. market entirely, triggering massive industry consolidation in India’s generic drug exports to the U.S. According to Ameliga Global Industrial Talent Center analysis, establishing overseas manufacturing facilities demands not only capital but also scarce expertise in international regulatory compliance, overseas operations, and FDA certification management—further widening the gap for Indian SMEs seeking U.S. transformation. 3.2 Five Structural Economic Barriers to U.S.-Based Production Relocation—All Difficult to Overcome in the Short Term Even if leading Indian pharmaceutical firms subjectively wish to build factories in the U.S. to circumvent tariffs, they face five formidable, economically rooted barriers in practice: production costs, industrial ecosystem support, labor supply, regulatory compliance, and capital investment. Barrier One: A Permanent Cost Gap in Production Comprehensive manufacturing costs in the U.S. are 40%–100% higher than in India. Labor-wise, salaries for skilled pharmaceutical workers in the U.S. are six to eight times those for equivalent positions in India; energy-wise, U.S. industrial electricity and natural gas prices significantly exceed those in Indian chemical industrial parks; land acquisition, factory construction, and fixed-asset depreciation costs likewise multiply. Generics that captured the U.S. market on cost advantages would see unit production costs surge post-localization—even tariff-free, their products would lose price competitiveness. For example, the U.S. production cost for a standard antihypertensive formulation rises from $0.80 per box in India to $1.70 per box domestically—erasing all prior cost advantages.

Investigation into India’s Pharmaceutical Industry — South Asia Edition

The biosimilars market is projected to grow at a compound annual growth rate (CAGR) of 22%, reaching $12 billion by 2025. India possesses a robust pharmaceutical industrial network, comprising 10,500 manufacturing units and over 3,000 pharmaceutical companies—including 650 facilities compliant with U.S. FDA standards, second only to the United States. In the active pharmaceutical ingredients (API) segment, India accounted for 8% of the global API industry as of November 2024. It produces over 500 distinct APIs and supplies 57% of WHO-prequalified APIs. India ranks among the world’s top 12 biotechnology nations. The sector was valued at $130 billion in 2024 and is projected to reach $300 billion by 2030. It hosts over 800 core biotech companies, more than 70 biotech incubators, and over 6,000 biotech startups. Based on this trajectory, the number of biotech startups is expected to surpass 10,000. The Indian government has set a target for the medical device industry: expanding its size from ₹102.564 billion (approximately $12 billion) in FY 2023–24 to ₹427.35 billion (approximately $50 billion) by 2030. Pharmaceutical Exports According to the Economic Survey 2025–26, India currently ranks 11th globally in pharmaceutical export value. In FY 2024–25, it exported medicines to 191 countries—with 50% of exports destined for highly regulated markets such as the U.S. and Europe—reflecting broad international acceptance of Indian pharmaceuticals. Pharmaceutical exports totaled $30.5 billion in FY 2024–25, representing nearly a 16-fold increase from $1.9 billion in FY 2000–01, with an annual compound growth rate exceeding 7%. Driven by rising demand from Europe, Africa, and Latin America, pharmaceutical exports reached $31.11 billion in FY 2026, marking a 2.13% increase over FY 2025. Under global demand and innovation momentum, the sector is projected to nearly double in size by 2030, reaching $130 billion. Some leading Indian pharmaceutical companies hold significant market shares in the U.S. In FY 2024–25, India exported approximately $9.7 billion worth of pharmaceuticals to the United States. Additionally, India exports medical devices to 187 countries; device exports surged from $2.5 billion in FY 2020–21 to $4.1 billion in FY 2024–25. India is also a global leader in vaccine supply: as of May 2025, it supplies 55–60% of vaccines to UNICEF, fulfills 99% of WHO’s demand for diphtheria-pertussis-tetanus (DPT) vaccines, and provides 52% of bacille Calmette-Guérin (BCG) vaccines and 45% of measles vaccines. Indian pharmaceutical exports still hold considerable growth potential: first, Indian firms have expanded exports to emerging markets, diversifying their overseas footprint; second, by innovating and upgrading their export portfolios—incorporating specialty generics, biosimilars, and novel drugs—they may shift from volume-driven to quality-driven export growth.

India's Cipla misses quarterly profit view on muted US sales

20 hours ago

India's Cipla missed Q2 profit estimates as net earnings fell to 8.78 billion rupees due to weak US sales of generic Revlimid. While North American revenue declined 19%, Indian operations grew 12%, partially offsetting the overall downturn.

reuters

2026-07-22

Indian drugmaker Cipla's Q1 profit misses estimates

2026-10-27

India's Cipla misses quarterly profit view on muted US sales

India's Cipla misses quarterly profit view on muted US sales

FAQ